Yükleniyor... / Loading...
This study evaluates the drug MK-8033 in patients with advanced solid tumors for whom standard treatment is insufficient. It included patients over 18 with adequate organ function. It was a Phase 1 study and has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * Patient must be at least 18 years of age, with adequate organ function, and an Eastern Cooperative Oncology Group (ECOG) performance of \<2 * Patient must be willing to undergo pre-study and post-dose tumor biopsy and have tumor accessible for biopsy (Waived during Parts A and C) Exclusion Criteria: * Patient is currently using bisphosphonate therapy or has received this therapy in past 6 months * Patient has had chemotherapy, radiotherapy, or biological therapy within 4 weeks of study participation * Patient has history of cardiac disease * Patient with a primary central nervous system tumor * Patient has a known psychiatric or substance abuse disorder * Patient is pregnant or breastfeeding, or expecting to conceive during the study * Patient is known to be Human Immunodeficiency Virus (HIV) positive and the HIV infection is not well controlled * Patient has received therapy with a Proton-Pump Inhibitor, Histamine2-Receptor antagonist or antacid within one week of study participation (Part B only)